IDSA Speaks... not mentioning their own role in the crisis

[Mort Zuckerman]

To: kathleen...@hhs.gov, francis...@nih.hhs.gov,
margaret...@fda.hhs.gov, dwh...@forbes.com,
ca...@drcarolgoodheart.com, lPick...@cdc.gov, Durlan...@yale.edu,
Aa...@columbia.edu, gary_w...@nymc.edu,
scientifi...@ostp.gov, pkru...@princeton.edu,
Stanle...@fiu.edu, margaret...@hhs.fds.gov,
emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@ct.gov, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, biz...@nytimes.com, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@ct.gov, kur...@washpost.com, georg...@washpost.com,
p...@allegorypress.com, commissi...@po.state.ct.us,
brans...@comcast.net, vts...@comcast.net, o...@po.state.ct.us,
freet...@charter.net, scott....@po.state.ct.us,
govern...@po.state.ct.us, attorney...@ct.gov,
randall...@usdoj.gov, Robert....@yale.edu, editor@greenwich-
post.com, harol...@yale.edu, sedm...@nswbc.org, rrmcg...@aol.com,
fr...@nytimes.com, saint....@sbcglobal.net
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, bmi...@newstimes.com, tr...@hotmail.com,
rast...@aol.com, billc...@gmail.com, amcg...@rms-law.com,
rjmu...@aol.com, paulcrai...@yahoo.com,
criminal...@usdoj.gov, karla.d...@usdoj.gov,
christophe...@usdoj.gov, richar...@yale.edu,
harol...@yale.edu, james.p...@yale.edu, inq...@aldf.com,
ly...@idsociety.org, meganm...@theatlantic.com

Subject: IDSA Speaks... not mentioning their own role in the crisis

Date: Jan 20, 2012 11:18 AM

ARTICLE BELOW
============================

Well, let's see.

When were any of IDSA's Rx-ing "MDs"
ever involved in Pharma's antimicrobials
development?

Never.

They only run clinical trials *FOR* BigPharma.
They have absolute ZERO to do with drug design.

IDSA knows so little about mechanisms of illness
that they have never told us - or anyone else -
what OspA even *is*, except when they reported
that it caused a multisystem disease, identical
to Chronic Lyme:
http://groups.google.com/group/sci.med.diseases.lyme/browse_thread/thread/a104a20c56109c33?hl=en#

======


BEN LUFT AND SMITHKLINE'S DENNIS PARENTI
AT THE 1998 FDA LYMERIX MEETING ADMITTING
TO LYME AND LYMERIX BEING THE SAME DISEASE:


BEN LUFT and SmithKline's Dennis Parenti at the 1998 FDA Vaccine
Meeting on LYMErix saying "LYMErix-Disease was the same as Lyme
Disease," and that "you can't use the Dearborn diagnostic standard to
diagnose Lyme"


http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3422t1.rtf


LUFT: "The point that I wanted to make in regard to the study is that
***there is very heavy dependence on serologic confirmation***. "And
when we start thinking about the adverse events, it was stated
originally when we got the overview of the disease that the disease
is
really quite protean. And actually the adverse events are very
similar to what the disease manifestations are. And if you start to,
as I think Dr. Hall was eluding to -- if you start to kind of say
well
how often do you actually become sero positive, you can start to have
a different take on when someone has an adverse event of whether it
is
disease specific or infection specific versus vaccine specific. And I
think that that is an important issue that we have to deal with.***"
I can only say from my own experience, having done a randomized
double-
blind controlled study that was FDA approved regarding the comparison
of ezithromycin to amoxicillin, when we found that azithromycin was
not as effective as amoxicillin, those patients when they had their
disease related events were sero negative at the time that they had
those events. So the serologic criteria would not have -- they would
have done very well actually with these criteria, and I think Pfizer
would have been much happier with me than they turned out to be."


LUFT: "So I just wanted to kind of ask in regard to that, and I think
it goes back to an earlier question that I asked in regard to the
self-
reported events and ***whether there was any segregation that
occurred
between the 10 percent of patients reporting that they were having
symptomatology, whether there was any difference between the vaccine
group and the placebo group independent of antibody or serologic
diagnosis."***


DR. PIETRUSKO: Dr. Parenti?


DR. PARENTI (SMITHKLINE): ***"Basically the two groups [Lyme and
LYMErix-Adverse Events-- KMD] had the same suspect symptoms.*** We
didn't put it through statistical rigor, but when you looked at what
it is that people came into the office with, what complaints, there
was basically the same complaints in both groups. So both groups
were
being evaluated for the same things."
http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3422t1.rtf


=========

Given all of the above, we wonder what the
hell IDSA is talking about. They obscure
all the data anyone needs about antibiotics
efficacy, mechanisms of illness, and any potential
vaccines.

And they have done so since 1992, when someone
sent Allen Steere on his European junket to
lie about how to diagnose Lyme:
http://www.actionlyme.org/STEERE_IN_EUROPE.htm

That is 20 years of lies, bullshit, harm
deaths, deaths from ALS-Lyme
http://www.actionlyme.org/ALSLYME47.htm
Leukemia, Lupus, MS, and cancer (since
most of the problem seems to be activated
Epstein-Barr- EBV activated by LYMErix:
http://www.actionlyme.org


And what did IDSA have to do with the pandemic
of MRSA-related deaths and dismemberments?

Everything.

The lied about the outcome of LYMErix, the
mechanisms of illness induction being the
same as the immunosuppression caused by
Staph aureus and other TLR2 agonists.

In short, IDSA promoted a vaccine that would
increase antimicrobial resistance and did not
prevent Lyme.

In short, IDSA's lies about Lyme and LYMErix
contributed to the lack of progress in every
major disease, including HIV, Tb, and MRSA:
http://www.actionlyme.org/SEBELIUS_TARDCARE_CRIME.htm

They, below, say they want regulation.

We agree.

We agreed when Sebelius uttered her retarded
nonsense about Obamacare in the wake of the
BMJ calls for SCIENTIFIC FRAUD PROSECUTIONS:
http://www.actionlyme.org/SEBELIUS_TARDCARE_CRIME.htm


In the form of *homicide* prosecutions.

KMDickson
http://www.actionlyme.org
--------------------------------------------

http://www.eurekalert.org/pub_releases/2012-01/idso-ads011812.php

Public release date: 20-Jan-2012
[ Print | E-mail | Share ] [ Close Window ]

Contact: John Heys
jh...@idsociety.org
703-299-0412
Infectious Diseases Society of America

Anti-infective drug shortages pose threat to public health and patient
care
[EMBARGOED FOR JAN. 20, 2012] Shortages of key drugs used to fight
infections represent a public health emergency and can put patients at
risk, according to a review published in Clinical Infectious Diseases
and available online. Frequent anti-infective shortages can
substantially alter clinical care and may lead to worse outcomes for
patients, particularly as the development of new anti-infectives has
slowed and the prevalence of multidrug-resistant pathogens is
increasing.

Of the 193 medications unavailable in the U.S. at the time of the
analysis, 13 percent were anti-infective drugs, the authors found, led
by Marc Scheetz, PharmD, and Milena Griffith, PharmD, from Midwestern
University Chicago College of Pharmacy and Northwestern Memorial
Hospital in Chicago. "Anti-infectives often represent irreplaceable
life-saving treatments," the authors noted, and hospitalized patients
are particularly vulnerable in an era when such shortages often last
months and are occurring more frequently.

First-line treatments for herpes encephalitis, neurosyphilis,
tuberculosis, and enterococcal infections, among others, have been hit
by shortages, forcing physicians to use other drugs that may not work
as well, the authors found. For example, the current shortage of the
intravenous form of sulfamethoxazole/trimethoprim, a first-line
treatment for Pneumocystis jiroveci pneumonia since the 1980s, may
result in adverse outcomes for patients with severe disease.

Although the root cause of drug shortages can be hard to determine—
current U.S. law does not require manufacturers to disclose such
details—the authors point to several supply-side issues that play a
role: procuring raw materials, processing, distributing, regulatory
compliance, market shortages due to epidemics, new therapeutic
indications, and perceived shortages.

Multidisciplinary stewardship programs that support the appropriate
"selection, dosing, route of administration, and duration of
antimicrobial therapy" can help front-line clinicians when a first-
line anti-infective drug is in short supply, Scheetz said. Hospitals
should also develop strategies that anticipate the impact and extent
of drug shortages, as well as identify therapeutic alternatives that
mitigate potential adverse outcomes.

Enhancing oversight by the Food and Drug Administration through
congressional legislation may also be needed to identify and correct
shortages of life-saving anti-infective drugs, conclude the authors,
who describe recently introduced legislation on this topic. "Let your
members of Congress know that addressing this issue is important for
the proper care of patients," Scheetz said.


###

Clinical Infectious Diseases is a leading journal in the field of
infectious disease with a broad international readership. The journal
publishes articles on a variety of subjects of interest to
practitioners and researchers. Topics range from clinical descriptions
of infections, public health, microbiology, and immunology to the
prevention of infection, the evaluation of current and novel
treatments, and the promotion of optimal practices for diagnosis and
treatment. The journal publishes original research, editorial
commentaries, review articles, and practice guidelines and is among
the most highly cited journals in the field of infectious diseases.
Clinical Infectious Diseases is an official publication of the
Infectious Diseases Society of America (IDSA). Based in Arlington,
Va., IDSA is a professional society representing more than 9,000
physicians and scientists who specialize in infectious diseases. For
more information, visit www.idsociety.org.





--------------------------------------------------------------------------------




KMDickson